Bevespi Aerosphere approved in China for COPD
18 May 2020 07:00 BST Bevespi Aerosphere approved in China for patients with COPD First approval in China of a fixed-dose, long-acting dual bronchodilator in a pressurised metered-dose inhaler device AstraZeneca's Bevespi Aerosphere (glycopyrronium/formoterol fumarate) has been approved in China as a maintenance treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. The approval by the National Medical Products Administration (NMPA) was based on positive results from the Phase III PINNACLE 4